From: Evaluation of miRNA-21 and CA-125 as a promising diagnostic biomarker in patients with ovarian cancer
N (50)
%
FIGO stage
I/II
30
60.0
III/IV
20
40.0
Histological type
Serous
Mucinous
14
28.0
Endometrioid
16
32.0
US
Bilateral
22
44.0
Multilocular
Solid
12
24.0
Metastasis
− ve
34
68.0
+ ve
16.0